BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36144246)

  • 1. Effect of Suppressive Levothyroxine Therapy on Bone Mineral Density in Young Patients with Differentiated Thyroid Carcinoma.
    Zanella AB; Marmitt L; Fighera TM; Scheffel RS; Spritzer PM; Dora JM; Maia AL
    Metabolites; 2022 Sep; 12(9):. PubMed ID: 36144246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
    Chen CH; Chen JF; Yang BY; Liu RT; Tung SC; Chien WY; Lu YC; Kuo MC; Hsieh CJ; Wang PW
    J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of thyroid stimulating hormone suppressive therapy on bone geometry in the hip area of patients with differentiated thyroid carcinoma.
    Moon JH; Jung KY; Kim KM; Choi SH; Lim S; Park YJ; Park DJ; Jang HC
    Bone; 2016 Feb; 83():104-110. PubMed ID: 26518742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low BMI and low TSH value as risk factors related to lower bone mineral density in postmenospausal women under levothyroxine therapy for differentiated thyroid carcinoma.
    de Melo TG; da Assumpção LV; Santos Ade O; Zantut-Wittmann DE
    Thyroid Res; 2015; 8():7. PubMed ID: 26097507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone mineral density and bone fracture in male patients receiving long-term suppressive levothyroxine treatment for differentiated thyroid carcinoma.
    Reverter JL; Colomé E; Holgado S; Aguilera E; Soldevila B; Mateo L; Sanmartí A
    Endocrine; 2010 Jun; 37(3):467-72. PubMed ID: 20960170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone mineral density and bone turnover markers in patients on long-term suppressive levothyroxine therapy for differentiated thyroid cancer.
    Lee MY; Park JH; Bae KS; Jee YG; Ko AN; Han YJ; Shin JY; Lim JS; Chung CH; Kang SJ
    Ann Surg Treat Res; 2014 Feb; 86(2):55-60. PubMed ID: 24761409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of TSH Suppression on Vertebral Trabecular Bone Scores in Patients With Differentiated Thyroid Carcinoma.
    Moon JH; Kim KM; Oh TJ; Choi SH; Lim S; Park YJ; Park DJ; Jang HC
    J Clin Endocrinol Metab; 2017 Jan; 102(1):78-85. PubMed ID: 27754806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trabecular bone score in women with differentiated thyroid cancer on long-term TSH-suppressive therapy.
    Sousa BÉCA; Silva BC; de Oliveira Guidotti T; Pires MC; Soares MMS; Kakehasi AM
    J Endocrinol Invest; 2021 Oct; 44(10):2295-2305. PubMed ID: 33730348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of TSH-suppressive doses of levothyroxine on bone mineral density in Thai women.
    Ongphiphadhanakul B; Puavilai G; Rajatanavin R
    J Med Assoc Thai; 1996 Sep; 79(9):563-7. PubMed ID: 8996984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone mineral density and bone microarchitecture after long-term suppressive levothyroxine treatment of differentiated thyroid carcinoma in young adult patients.
    Mendonça Monteiro de Barros G; Madeira M; Vieira Neto L; de Paula Paranhos Neto F; Carvalho Mendonça LM; Corrêa Barbosa Lima I; Corbo R; Fleiuss Farias ML
    J Bone Miner Metab; 2016 Jul; 34(4):417-21. PubMed ID: 26056020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone Mineral Density in Adult Survivors of Pediatric Differentiated Thyroid Carcinoma: A Longitudinal Follow-Up Study.
    Dekker BL; Muller Kobold AC; Brouwers AH; Williams GR; Nies M; Klein Hesselink MS; van der Horst-Schrivers ANA; Havekes B; van den Heuvel-Eibrink MM; van der Pal HJH; Plukker JTM; Ronckers CM; van Santen HM; Burgerhof JGM; Corssmit EPM; Netea-Maier RT; Peeters RP; van Dam EWCM; Boot AM; Tissing WJE; Bocca G; Links TP
    Thyroid; 2021 Nov; 31(11):1707-1714. PubMed ID: 34514857
    [No Abstract]   [Full Text] [Related]  

  • 12. Bone mineral density in treated at a young age for differentiated thyroid cancer after Chernobyl female patients on TSH-suppressive therapy receiving or not Calcium-D3 supplementation.
    Leonova TA; Drozd VM; Saenko VA; Mine M; Biko J; Rogounovitch TI; Takamura N; Reiners C; Yamashita S
    Endocr J; 2015; 62(2):173-82. PubMed ID: 25374130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma.
    Reverter JL; Holgado S; Alonso N; Salinas I; Granada ML; Sanmartí A
    Endocr Relat Cancer; 2005 Dec; 12(4):973-81. PubMed ID: 16322336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes of bone mineral density in pre-menopausal women with differentiated thyroid cancer receiving L-thyroxine suppressive therapy.
    Mazokopakis EE; Starakis IK; Papadomanolaki MG; Batistakis AG; Papadakis JA
    Curr Med Res Opin; 2006 Jul; 22(7):1369-73. PubMed ID: 16834835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trabecular bone deterioration in differentiated thyroid cancer: Impact of long-term TSH suppressive therapy.
    Hawkins Carranza F; Guadalix Iglesias S; Luisa De Mingo Domínguez M; Martín-Arriscado Arroba C; López Álvarez B; Allo Miguel G; Martínez Díaz-Guerra G
    Cancer Med; 2020 Aug; 9(16):5746-5755. PubMed ID: 32583973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The risk between thyrotropin suppression and bone mineral density in differentiated thyroid cancer.
    Zou Y; Li B; Wang X; Mao J; Zhang Y
    Medicine (Baltimore); 2022 Dec; 101(48):e31991. PubMed ID: 36482589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone mineral density during maintenance treatment with supraphysiological doses of levothyroxine in affective disorders: a longitudinal study.
    Bauer M; Fairbanks L; Berghöfer A; Hierholzer J; Bschor T; Baethge C; Rasgon N; Sasse J; Whybrow PC
    J Affect Disord; 2004 Dec; 83(2-3):183-90. PubMed ID: 15555712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of replacement doses of thyroxine on bone mineral density.
    Hanna FW; Pettit RJ; Ammari F; Evans WD; Sandeman D; Lazarus JH
    Clin Endocrinol (Oxf); 1998 Feb; 48(2):229-34. PubMed ID: 9579237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of thyrotropin suppression on lumbar bone mineral density in postmenopausal women with differentiated thyroid carcinoma.
    Zhang P; Xi H; Yan R
    Onco Targets Ther; 2018; 11():6687-6692. PubMed ID: 30349302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low trabecular bone score in postmenopausal women with differentiated thyroid carcinoma after long-term TSH suppressive therapy.
    De Mingo Dominguez ML; Guadalix Iglesias S; Martin-Arriscado Arroba C; López Alvarez B; Martínez Diaz-Guerra G; Martinez-Pueyo JI; Ferrero Herrero E; Hawkins Carranza F
    Endocrine; 2018 Oct; 62(1):166-173. PubMed ID: 30014437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.